Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.

Inclusion criteria

• Adult women from 20 through 39 years of age at the screening
• Subjects with the mean menstrual cycle day (MCD) of 25 to 35 days
• Subjects with the Follicle Stimulating Hormone (FSH) concentration at the screening not exceeding the upper limit of the normal range (ULN)
• Those diagnosed with infertility due to at least one of the following causes of infertility

• Fallopian tubal factor
• Infertility due to unknown cause
• Male infertility
• Complex factor
• Subjects with the normal ovarian and uterine function
• Subjects with not more than 3 times of the prior experience of in vitro fertilization
• Subjects who had neither administered clomiphene citrate within 30 days nor gonadotropin within 14 days of the IP administration day
• Subjects who were informed on the objective, method and effect etc. of the clinical study and signed the informed consent form

Exclusion criteria

• Subjects contraindicated to pregnancy
• Subjects with BMI > 30 (BMI; kg/m2)
• Subjects diagnosed with polycystic ovary syndrome (PCOS)
• Subjects who had experienced previously at least Grade 4 ovarian hyperstimulation syndrome (OHSS)
• Subjects with poor response to gonadotropin (According to the Bologna criteria* below) *At least two of the following three features must be present:

① Advanced maternal age (>=40 years) or any other risk factor for Poor Ovarian Response (POR)

② A previous POR (<=3 oocyte with a conventional stimulation protocol)

③ An abnormal ovarian reserve test (i.e. Antral follicle Count (AFC) < 5 follicles or Anti-Mullerian hormone (AMH) < 0.5 ng/ml)

• Those with abnormal metrorrhagia due to unknown cause at the screening
• Subjects with submucosal uterine leiomyoma
• Subjects with at least borderline ovarian tumor
• Subjects with a history or malignant tumor in breast
• Subjects with hydrosalpinx not removed by operation
• Subjects with the Thyroid Stimulating Hormone (TSH) level out of the normal range at the screening
• Subjects with a history of malignant tumor within 5 years prior to the screening
• Subjects with severe disease potentially affecting the study such as pituitary insufficiency upon the investigator's judgment (e.g., heart failure, renal failure, hepatic failure or adrenal insufficiency etc.)
• Subject with HIV- or syphilis-positive result at the screening
• Subjects with a psychiatric disorder at the screening or those who failed in understanding the objective and method of this clinical study
• Subject diagnosed with alcohol or drug abuse within 3 months prior to the screening
• Subjects with a history of hypersensitivity to the investigational products of this clinical study
• Subjects with a current or history of thromboembolism in vein or artery
• Subjects with a history of genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.
• Subjects who had participated in another clinical study related to a drug administration after the enrollment in this study or who had participated in another clinical study within 3 months prior to the enrollment in this study
• Others including the subjects for whom it was considered difficult to conduct this clinical study upon the principal investigator's judgment